| Authors: |
Rogers SL; School of Engineering Medicine, Texas A&M University, Houston, TX, USA.; Department of Translational Medical Sciences, School of Medicine, Texas A&M University, Bryan, TX, USA.; Center for Genomic and Precision Medicine, Institute of Biosciences and Technology, Texas A&M University, Houston, TX, USA.; American Society of Pharmacovigilance, Houston, TX, USA., Haga SB; Department of Medicine, Duke University School of Medicine, Program in Precision Medicine, 101 Science Drive, Durham, NC, 27708, USA., Yonekawa-Blest K; Peaceful Transitions, Houston, TX, USA., Merritt K; Advocates for Universal DPD/DPYD testing prior to fluorouracil based chemotherapy, Seattle, WA, USA., Shawn Jones J; Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center Jerry H. Hodge School of Pharmacy, Dallas, Texas, USA., Kong BL; Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA. kongb.rx@gmail.com., Ho TT; Department of Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. |
